Ayurvedic treatment of Allergic Rhinitis

Clinical evaluation of an Ayurvedic formulation in the management of Allergic Rhinitis-A pilot study

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/12/010937

Enrollment

Registered

2017-12-21

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Allergic Rhinitis

Interventions

Intervention1: Anu Taila NAsya Ashwagandhadhi Yoga Shirishadi Kwatha: 1) Anutaila- Nasya (6 drops in each nostril) -Ref.-A.H.Su.20/16 Dose : 06 ml Dosage form : Oil

Eligibility

Inclusion criteria

Inclusion criteria: Patients either sex aged between 18 to 65 years. 2. Clinical diagnosis persisting symptoms of Allergic rhinitis, X-ray (PNS), Nasal endoscopy and laboratory investigations etc. 3. Able and willing to participate and provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. History of chronic nasal or upper respiratory tract symptoms or disorders other than allergic rhinitis. 2. History of non allergic rhinitis, chronic sinusitis or serve asthma. 3. Patients with nasal anatomical defects (deviated nasal septum). 4. Patients with acute episodes i.e. fever/earache/headache. 5. Patients with associated tonsillitis or airway obstructions (adenoids). 6. Has a nasal condition likely to affect the outcome of the study. 7. Any treatment of H1 antihistamine medication, Non-steroidal analgesies. Corticosteroids Nasal drops, Leukotriene antagonists, Nasal vasoconstrictors. 8. Pregnant ladies and Lactating mothers. 9. Patients suffering from any debilitating chronic disease like tuberculosis, Uncontrolled Diabetes mellitus 10. Any unstable cardio-vascular diseases 11. Patients with evidence of malignancy. 12. Patients with concurrent hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT) > 2 times upper normal limit or Renal Disorders (defined as S. creatinine > upper limit of Lab. value), Pulmonary Dysfunction (Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]) 13. Patient has an acute mental disorder 14. Patients who are currently participating in any other clinical trial.

Design outcomes

Primary

Measure	Time frame
To evaluate the effect of Ayurvedic formulation in terms of Control of Allergic Rhinitis and Asthma TestTimepoint: one month	—

Secondary

Measure	Time frame
Not applicableTimepoint: Not applicable	—

Countries

India

Contacts

Public ContactDr Mata Shweta Pradipbhai

Central Ayurveda Research Institute for Cardiovascular Diseases New Delhi

shwetamatadr@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026